Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

1.

No significant viral transcription detected in whole breast cancer transcriptomes.

Fimereli D, Gacquer D, Fumagalli D, Salgado R, Rothé F, Larsimont D, Sotiriou C, Detours V.

BMC Cancer. 2015;15(1):1176. doi: 10.1186/s12885-015-1176-2. Epub 2015 Mar 18.

2.

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J.

J Clin Oncol. 2015 Jan 5. pii: JCO.2014.55.2158. [Epub ahead of print]

PMID:
25559818
3.

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B.

BMC Genomics. 2014 Nov 21;15:1008. doi: 10.1186/1471-2164-15-1008.

4.

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors.

Sonnenblick A, Fumagalli D, Azim HA Jr, Sotiriou C, Piccart M.

Clin Cancer Res. 2014 Dec 15;20(24):6242-6. doi: 10.1158/1078-0432.CCR-14-1086. Epub 2014 Oct 21.

PMID:
25336696
5.

Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data.

Lönnstedt IM, Caramia F, Li J, Fumagalli D, Salgado R, Rowan A, Salm M, Kanu N, Savas P, Horswell S, Gade S, Loibl S, Neven P, Sotiriou C, Swanton C, Loi S, Speed TP.

Genome Biol. 2014 Oct 1;15(9):470. doi: 10.1186/s13059-014-0470-7.

6.

The AURORA initiative for metastatic breast cancer.

Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart M.

Br J Cancer. 2014 Nov 11;111(10):1881-7. doi: 10.1038/bjc.2014.341. Epub 2014 Sep 16. Review.

7.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M.

Ann Oncol. 2014 Oct;25(10):1959-65. doi: 10.1093/annonc/mdu288. Epub 2014 Jul 25.

PMID:
25185240
8.

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Sonnenblick A, Fumagalli D, Sotiriou C, Piccart M.

Cancer Treat Rev. 2014 Oct;40(9):1089-95. doi: 10.1016/j.ctrv.2014.07.005. Epub 2014 Aug 12. Review.

PMID:
25151406
9.

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M.

J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21. Review.

PMID:
25049332
10.

Modelling soil borne fungal pathogens of arable crops under climate change.

Manici LM, Bregaglio S, Fumagalli D, Donatelli M.

Int J Biometeorol. 2014 Dec;58(10):2071-83. doi: 10.1007/s00484-014-0808-6. Epub 2014 Mar 11.

PMID:
24615638
11.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

PMID:
24608200
12.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S.

J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8. doi: 10.1093/jnci/djt321. Epub 2013 Nov 21.

13.

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C.

J Natl Cancer Inst. 2013 Jul 3;105(13):960-7. doi: 10.1093/jnci/djt121. Epub 2013 Jun 5.

14.

Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.

Azim HA Jr, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart M, Michiels S, Sotiriou C.

PLoS One. 2013 Apr 26;8(4):e62451. doi: 10.1371/journal.pone.0062451. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/3d5a5933-791f-4191-98f5-f559a872e404.

15.

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL.

Clin Cancer Res. 2012 Dec 1;18(23):6531-41. doi: 10.1158/1078-0432.CCR-12-0605. Epub 2012 Oct 8.

16.

Genomic grade adds prognostic value in invasive lobular carcinoma.

Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart M, Sotiriou C.

Ann Oncol. 2013 Feb;24(2):377-84. doi: 10.1093/annonc/mds280. Epub 2012 Oct 1.

17.

Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?

Fumagalli D, Andre F, Piccart-Gebhart MJ, Sotiriou C, Desmedt C.

Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e58-69. doi: 10.1016/j.critrevonc.2012.08.003. Epub 2012 Sep 7. Review.

PMID:
22964299
18.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Zardavas D, Fumagalli D, Loi S.

Curr Opin Oncol. 2012 Nov;24(6):623-34. doi: 10.1097/CCO.0b013e328358a2b5. Review.

PMID:
22960556
19.

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration.

Lancet Oncol. 2012 Jun;13(6):e240-8. doi: 10.1016/S1470-2045(11)70378-3.

PMID:
22652232
20.

Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE.

Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, Ferrero S, Perego R, Bianchi C, Sarto C, Pitto M, Brambilla P, Magni F.

Mol Biosyst. 2012 Apr;8(4):1040-51. doi: 10.1039/c2mb05390j. Epub 2012 Feb 8.

PMID:
22315040
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk